Quantitative Proteomic Analysis Of Faecal Biomarkers For Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$562,398.00
Summary
We have identified a number of potential biomarkers present in the stools of patients with colorectal cancer (CRC). We will use quantitative mass spectrometric techniques that we have developed to validate these biomarkers on a large number of faecal samples from patients with CRC and multiple control groups. We believe these studies will lead to a new panel of biomarkers which will improve the detection of early forms of colon cancer, thus reducing death from this disease.
Prognostic Importance Of Androgen Receptors In Epithelium And Stroma In Early Stage Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$348,750.00
Summary
The use of serum prostate specific antigen (PSA) to screen asymptomatic men for prostate cancer has reduced the stage of disease at diagnosis. The majority of tumours are now small and potentially organ-confined. The use of nomograms, algorithms based on preoperative clinical features of these patients (serum PSA level, Gleason grade, clinical stage) has facilitated this process, but is imperfect as 20-30% of patients experience disease relapse within 5-7 years. Tumours with similar preoperative ....The use of serum prostate specific antigen (PSA) to screen asymptomatic men for prostate cancer has reduced the stage of disease at diagnosis. The majority of tumours are now small and potentially organ-confined. The use of nomograms, algorithms based on preoperative clinical features of these patients (serum PSA level, Gleason grade, clinical stage) has facilitated this process, but is imperfect as 20-30% of patients experience disease relapse within 5-7 years. Tumours with similar preoperative clinical features have markedly different outcomes, reinforcing the inadequacy of current approaches to determining whether or not an individual patient has organ-confined disease. A new approach is to incorporate into the standard diagnostic nomograms, biological features from preoperative core biopsy linked to the process of disease relapse, and which independently predict patient outcome risk group. Our preliminary studies using a small hypothesis-generating cohort of patients with early stage prostate cancer determined that elevated levels of androgen receptors (AR) in malignant epithelial cells and reduced levels of AR in peritumoral stromal cells independently predict disease relapse after surgery. In this project, AR measurements will be analysed in independent cohorts of patients derived from two Australian institutions to determine whether the predictive value is maintained across multi-Institutional cohorts. Selected androgen-regulated markers of tumour growth and spread (proliferative, apoptotic, metastatic) will be examined in microarrayed postoperative tissue samples. The postoperative markers will be examined for independence of prediction of relapse. Independent markers will be examined for ability to increase predictive efficacy in standard diagnostic nomograms. Levels of the two markers with greatest predictive value will be measured in preoperative core biopsies and tested for predictive ability as a prelude to clinical practice.Read moreRead less
Randomized Controlled Trial Of A Video-delivered Intervention For The Early Detection Of Melanoma In Men 50+ Years
Funder
National Health and Medical Research Council
Funding Amount
$511,694.00
Summary
Unfortunately, men over 50 years are most at risk to die from melanoma. Skin self-examination, where a man inspects the skin of his whole body with the help of a mirror or another person, and rapid presentation to a doctor without delay if he detects a suspicious lesion has the potential to increase awareness for the skin and to improve early diagnosis. We want to assess if we can increase the rate of skin self-examination in men 50 years and over through a video-delivered intervention.
Crossover Trial Of Dermoscopy And Short-term Digital Monitoring For The Management Of Skin Lesions In General Practice
Funder
National Health and Medical Research Council
Funding Amount
$192,000.00
Summary
Australia has the highest incidence of melanoma in the world. Early detection of melanoma is critical in reducing the death rate from melanoma. Currently the diagnostic accuracy of melanoma in general practice is poor with around 30 benign lesions being cut out for every one melanoma. This severely impacts on the total health budget, with a cost of $46M per annum in general practice. An improved diagnostic method for detecting melanoma of the skin will allow earlier detection of melanoma and dec ....Australia has the highest incidence of melanoma in the world. Early detection of melanoma is critical in reducing the death rate from melanoma. Currently the diagnostic accuracy of melanoma in general practice is poor with around 30 benign lesions being cut out for every one melanoma. This severely impacts on the total health budget, with a cost of $46M per annum in general practice. An improved diagnostic method for detecting melanoma of the skin will allow earlier detection of melanoma and decrease the rate of needless excision biopsies.Read moreRead less
SNAC2: A Randomised Trial Of Extending Sentinel Node Based Management To Women With Larger Or Multifocal Breast Cancers
Funder
National Health and Medical Research Council
Funding Amount
$1,266,430.00
Summary
SNAC2 extends the work begun in SNAC1, which recruited 1,088 women over 4 years. SNAC1 will determine if sentinel node biopsy causes less arm problems than axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours. SNAC2 is needed to determine whether the smaller operation gives cure rates as good as axillary clearance. If it does, then it will become standard practice.
A Randomised Controlled Trial Comparing Intraoperative To Conventional Radiotherapy In Women With Early Beast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$874,046.00
Summary
With the advent of breast screening in Australia many women are diagnosed with small low risk cancers that can be treated with breast conserving therapy with good outcomes. Surgery and radiotherapy in this situation are used to minimise the risk of local recurrence. It is now being questioned whether we can tailor radiotherapy to suit individual patients rather than recommending the daily 6-7 weeks of standard external beam radiotherapy to all patients. This trial aims to answer this question as ....With the advent of breast screening in Australia many women are diagnosed with small low risk cancers that can be treated with breast conserving therapy with good outcomes. Surgery and radiotherapy in this situation are used to minimise the risk of local recurrence. It is now being questioned whether we can tailor radiotherapy to suit individual patients rather than recommending the daily 6-7 weeks of standard external beam radiotherapy to all patients. This trial aims to answer this question as a new device which can deliver radiotherapy intraoperatively in a single session has now been tested and proven safe to use in the breast. The main objective of this trial is to demonstrate that a single dose of radiotherapy delivered intraoperatively (IORT) gives an equivalent local control rate to standard external beam radiotherapy in women with early low risk breast cancer who are suitable for breast conserving therapy. Other objectives include comparing the two treatments with respect to; disease-free-overall survival, cosmetic outcome, patient satisfaction-preference, quality of life and cost benefit. If the study finds that IORT alone after breast conserving surgery is as effective in achieving local control as standard external beam radiotherapy, a major benefit to patients would be shorter treatment duration by avoiding the 6-7 weeks of standard radiotherapy. A reduction in the number of early breast cancer patients requiring access to standard radiotherapy would also benefit treatment centres and other cancer patients by reducing the waiting times for radiotherapy. Consumer groups have supported the concept from the beginning and there has been recent increase in level of support by originally unsupportive groups. Of great significance is this trial offers an opportunity to formally investigate the efficacy of delivering IORT in the safe confines of a clinical trial, before allowing it to become a standard treatment which is occurring in other countries.Read moreRead less
Re-participation In Screening For Colorectal Cancer: Behavioural Outcomes And Predictors.
Funder
National Health and Medical Research Council
Funding Amount
$687,438.00
Summary
Screening for bowel cancer (CRC) is an important public health initiative. It is most effective when undertaken regularly but there is little research on what personal factors relate to ongoing participation in a screening program. This study will determine the factors associated with ongoing participation in CRC screening and will lead to better screening programs and improved health benefits. This study directly addresses the Cancer Australia priority area re improving screening programs.
MICRORNA PREDICTORS OF OESOPHAGEAL TUMOUR RESPONSE TO CHEMOTHERAPY AND RADIOTHERAPY
Funder
National Health and Medical Research Council
Funding Amount
$659,990.00
Summary
Chemoradiotherapy (CRT) is used for the treatment of oesophageal cancer before surgical resection, and for patients not undergoing surgery. However, it is unsuccessful for many, causing side effects, no clinical gain, and delaying surgery. MicroRNAs are small molecules that control cellular functions. This project will identify miRNA markers which are able to predict cancer response to CRT, and this will help clinical decision making for individualized treatment.
Development Of High-throughput Screening Assays For Detecting Early Gastric Cancer: Translating Proteomics Research Into Clinical Outcomes Using Emerging Mass Spectrometry And Photonics Technologies
Funder
National Health and Medical Research Council
Funding Amount
$655,438.00
Summary
Gastric cancer (GC) is the second leading cause of cancer death worldwide, claiming the lives of >11,000 Australians from 1996-2006. Individuals diagnosed with GC have an expected 5-year survival rate of 10-30%. This could be improved if cases were identified in the early stages of the disease where treatments are more effective. Researchers from Adelaide and Melbourne are developing a diagnostic assay for early-stage GC based on a novel detection system that requires only a drop of blood.